Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePractice

Palivizumab for the prevention of respiratory syncytial virus infection

Alexander L. Rogovik, Bruce Carleton, Alfonso Solimano and Ran Goldman
Canadian Family Physician August 2010; 56 (8) 769-772;
Alexander L. Rogovik
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce Carleton
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfonso Solimano
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran Goldman
MD FRCPC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rgoldman@cw.bc.ca
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    Table 1.

    Indications for administering palivizumab for RSV prophylaxis

    PALIVIZUMAB USECRITERIA
    RoutineChildren younger than 2 years of age with CLD due to prematurity who require ongoing medical therapy (oxygen, steroids, or daily bronchodilator therapy) within the 6 months preceding the RSV season
    Children younger than 2 years of age with hemodynamically significant cyanotic and acyanotic heart disease
    Infants born at 32 weeks’ gestation or earlier who are 6 months of age or younger (with or without CLD) at the start of the RSV season
    Children in isolated northern or rural remote communities (eg, children who require air transportation to hospital facilities), born before 36 weeks’ gestation, if they are younger than 6 months of age at the onset of RSV season
    DiscretionaryFull-term Inuit infants younger than 6 months of age at the onset of the RSV season in northern remote communities (eg, children who require air transportation to hospital facilities), regardless of gestational age
    Some patients with severe CLD or congenital heart disease, who require ongoing medical therapy
    Children with severe immunodeficiency diseases and those with other rare conditions, such as Down syndrome, at high risk of developing severe disease with RSV in the first year of life
    • CLD—chronic lung disease, RSV—respiratory syncytial virus.

    • Data from Samson et al.14

PreviousNext
Back to top

In this issue

Canadian Family Physician: 56 (8)
Canadian Family Physician
Vol. 56, Issue 8
1 Aug 2010
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Palivizumab for the prevention of respiratory syncytial virus infection
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Palivizumab for the prevention of respiratory syncytial virus infection
Alexander L. Rogovik, Bruce Carleton, Alfonso Solimano, Ran Goldman
Canadian Family Physician Aug 2010, 56 (8) 769-772;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Palivizumab for the prevention of respiratory syncytial virus infection
Alexander L. Rogovik, Bruce Carleton, Alfonso Solimano, Ran Goldman
Canadian Family Physician Aug 2010, 56 (8) 769-772;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Variability in indications
    • Clinical trials
    • Adverse effects
    • Indications
    • Conclusion
    • Notes
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Hypoxia inducible factors inhibit respiratory syncytial virus infection by modulation of nucleolin expression
  • Palivizumabs real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017
  • Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors
  • Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera
  • Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection
  • Google Scholar

More in this TOC Section

Practice

  • Determining if and how older patients can safely stay at home with additional services
  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
Show more Practice

Child Health Update

  • Accidental cannabis ingestion in young children
  • All-terrain vehicle injuries in children and adolescents
  • Screen time and sleep in children
Show more Child Health Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire